All In Biotech

Drug Trial Radar · NCT06365437

A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation

A 12-Month, Randomized, Controlled, Open-Label, Dose Escalation Study Evaluating Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of an Anti-CD2 Monoclonal Antibody, TCD601 (Siplizumab) Compared to Anti-thymocyte Globulin (rATG), as Induction Therapy in de Novo Renal Transplant Recipients

Last checked: Nov 20, 2026Latest source record: Mar 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

33

Actual

Start

Jun 6, 2021

Primary completion

Dec 11, 2024

Study completion Dec 11, 2024

Sponsor

Lead sponsor
ITB-Med LLCIndustry
Sponsor type
Industry
First posted
Apr 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of TCD601 when compared to rATG in de novo renal transplant patients.

Conditions

  • Kidney Transplantation

Interventions

  • TCD601Biological

    Investigational Product

  • Tacrolimus (TAC)Drug

    Standard of Care Concomitant Immunosuppression

  • Corticosteroids (CS)Drug

    Standard of Care Concomitant Immunosuppression

  • Mycophenolate Mofetil (MMF)Drug

    Standard of Care Concomitant Immunosuppression

  • ATGDrug

    Standard of Care induction therapy in solid organ transplantation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v5.0.Time frame: 12 months
  2. Measure Peak TCD601 Plasma Concentration (Cmax) Over Time.Time frame: 12 months
  3. Measure the Area Under the TCD601 Plasma Concentration Versus Time Curve (AUC).Time frame: 12 months

Locations

7 sites in 3 countries. Site status is shown where the registry gives one.

  • Innsbruck Medical University

    Innsbruck, Austria

  • University of Vienna

    Vienna, Austria

  • Hospital Clinic de Barcelona

    Barcelona, Spain

  • Hospital Universitari de Bellvitge

    Barcelona, Spain

  • Sahlgrenska University Hospital

    Gothenburg, Sweden

  • Skåne University Hospital

    Malmö, Sweden

  • Karolinska University Hospital

    Stockholm, Huddinge, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.